A significant regulatory decision has injected fresh optimism into the beleaguered U.S. health insurance sector, with industry giant UnitedHealth Group positioned as a primary beneficiary. The Centers for Medicare & Medicaid Services (CMS) finalized a far more generous payment rate adjustment than initially proposed, authorizing an average net increase of 2.48% for the crucial Medicare Advantage program in 2027. This final figure starkly contrasts with the mere 0.09% hike floated in January, a move analysts estimate will funnel an additional $13 billion into the private sector.
This regulatory relief arrives at a critical juncture for UnitedHealth. The company’s Medical Care Ratio (MCR), a key metric showing the percentage of premium revenue spent on medical care, climbed to an elevated 89% last year, pressured by a significant rise in patient treatment utilization. Historically, a ratio around 80% is more typical. The newly approved financial buffer is seen as essential for stabilizing this expense ratio in the coming years.
Concurrently, UnitedHealth’s management is executing a deliberate internal overhaul, prioritizing profitability over sheer membership growth. The company plans to shed between 2.3 and 2.8 million unprofitable members from its Medicare Advantage and Medicaid segments this year. This strategic pruning aims to support the MCR, which the company is targeting to reduce to 88.8% by 2026. Management notes that approximately 90% of the planned pricing adjustments in its UnitedHealthcare segment are already finalized for early 2026.
The improved outlook prompted several investment banks to swiftly revise their assessments. Bernstein reaffirmed its “Outperform” rating with a $411 price target, while Raymond James upgraded the stock to “Outperform” with a $330 target. HSBC moved its rating to “Hold” with a $300 target. Bank of America maintained its “Neutral” stance but raised its price objective to $337.
Should investors sell immediately? Or is it worth buying Unitedhealth?
Market sentiment shifted noticeably following the CMS announcement. After a prolonged downtrend that has left the stock down roughly 50% year-to-date, shares rallied, posting a weekly gain of 10.19%. The stock closed at 265.00 euros on Wednesday, putting noticeable distance between itself and its 50-day moving average of 243.80 euros.
All eyes now turn to the upcoming first-quarter earnings report scheduled for April 21, 2026. This release will serve as the first concrete test of UnitedHealth’s dual-pronged strategy, revealing whether the shedding of unprofitable contracts is sufficient to offset historic cost pressures. It will also provide early data on how management integrates the new government payment rates into its future pricing.
For the full 2026 fiscal year, UnitedHealth has provided the following guidance: adjusted earnings per share are projected above $17.75, compared to $16.35 the prior year; revenue is expected to exceed $439 billion; and the operating profit growth for its Optum Health segment is targeted at 9%.
Ad
Unitedhealth Stock: Buy or Sell?! New Unitedhealth Analysis from April 9 delivers the answer:
The latest Unitedhealth figures speak for themselves: Urgent action needed for Unitedhealth investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 9.
Unitedhealth: Buy or sell? Read more here...
